Third-Line Treatment Options for Metastatic Colorectal Cancer - Episode 5

Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

,

Panelists discuss how health-related quality of life (HRQOL) data influence their treatment decisions for third-line metastatic colorectal cancer (mCRC), how they assess patient symptoms and quality of life in clinical practice, and how the toxicity profiles of different therapies guide their treatment choices.

EP. 1: Navigating mCRC: Treatment Options in the Third-Line Setting
EP. 2: Nuances With Defining “Refractory” mCRC in the Third-Line Setting
EP. 3: Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients
EP. 4: Perspectives on the SUNLIGHT Trial: Study Design and Outcomes
Now Viewing
EP. 5: Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection
EP. 6: Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab
EP. 7: Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment
EP. 8: Unmet Needs in Third-Line mCRC: Challenges and Opportunities
  1. How do the reported HRQOL data influence your treatment decisions? And how do you assess your patient’s symptoms or quality of life in a real-life practice setting?
  2. How does the toxicity profile of each agent influence your treatment selection?

Related Content:

Third-Line Treatment Options for Metastatic Colorectal Cancer
Unmet Needs in Third-Line mCRC: Challenges and Opportunities
Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment
Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab